Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shibu Thomas

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Cancer Research|December 15, 2010
Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancerShibu Thomas, Jonathan B Overdevest, Matthew D Nitz, et al.
Bioorganic & Medicinal Chemistry|January 29, 2008
Biocatalytic and semisynthetic optimization of the anti-invasive tobacco (1S,2E,4R,6R,7E,11E)-2,7,11-cembratriene-4,6-diolKhalid A El Sayed, Surat Laphookhieo, Hany N Baraka, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|February 15, 2020
Investigation of flow dynamics of primary coolant in a delay tank of a swimming pool-type nuclear reactor using radiotracer techniqueHarish Jagat Pant, Sunil Goswami, Vijay Kumar Sharma, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 27, 2012
CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulatedJonathan B Overdevest, Kristina H Knubel, Jason E Duex, et al.
Expert Opinion on Therapeutic Targets|November 24, 2012
Targeting the Bcl-2 family for cancer therapyShibu Thomas, Bridget A Quinn, Swadesh K Das, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2026
Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and <i>FGFR</i> Alterations: Final Results From the Phase II NORSE StudyYohann Loriot, Thomas Powles, Victor Moreno, et al.
Cancer Medicine|February 26, 2025
Prognostic Impact of Oncogenic Fibroblast Growth Factor Receptor Alterations in Patients With Advanced Solid Tumors in a Real-World SettingLevon Demirdjian, Spyros Triantos, Kristopher Standish, et al.
Prostate Cancer|October 10, 2022
Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate CancerRahul Aggarwal, Joshi J Alumkal, Russell Z Szmulewitz, et al.
European Urology|December 17, 2021
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTANFred Saad, Eric J Small, Felix Y Feng, et al.
JAMA Oncology|June 3, 2021
Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate CancerFelix Y Feng, Shibu Thomas, Fred Saad, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Cancer Research|December 15, 2010
Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancerShibu Thomas, Jonathan B Overdevest, Matthew D Nitz, et al.
Bioorganic & Medicinal Chemistry|January 29, 2008
Biocatalytic and semisynthetic optimization of the anti-invasive tobacco (1S,2E,4R,6R,7E,11E)-2,7,11-cembratriene-4,6-diolKhalid A El Sayed, Surat Laphookhieo, Hany N Baraka, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|February 15, 2020
Investigation of flow dynamics of primary coolant in a delay tank of a swimming pool-type nuclear reactor using radiotracer techniqueHarish Jagat Pant, Sunil Goswami, Vijay Kumar Sharma, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 27, 2012
CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulatedJonathan B Overdevest, Kristina H Knubel, Jason E Duex, et al.
Expert Opinion on Therapeutic Targets|November 24, 2012
Targeting the Bcl-2 family for cancer therapyShibu Thomas, Bridget A Quinn, Swadesh K Das, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2026
Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and <i>FGFR</i> Alterations: Final Results From the Phase II NORSE StudyYohann Loriot, Thomas Powles, Victor Moreno, et al.
Cancer Medicine|February 26, 2025
Prognostic Impact of Oncogenic Fibroblast Growth Factor Receptor Alterations in Patients With Advanced Solid Tumors in a Real-World SettingLevon Demirdjian, Spyros Triantos, Kristopher Standish, et al.
Prostate Cancer|October 10, 2022
Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate CancerRahul Aggarwal, Joshi J Alumkal, Russell Z Szmulewitz, et al.
European Urology|December 17, 2021
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTANFred Saad, Eric J Small, Felix Y Feng, et al.
JAMA Oncology|June 3, 2021
Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate CancerFelix Y Feng, Shibu Thomas, Fred Saad, et al.
Pageof 5